#United States #Kessler Topaz #Securities Fraud #Radnor #Soleno Therapeutics

Overview of the Lawsuit Against Soleno Therapeutics

Kessler Topaz Meltzer & Check, LLP, a prominent law firm specializing in securities litigation, has initiated a notification for investors who might have faced losses due to investments in Soleno Therapeutics, Inc. (NASDAQ: SLNO). According to the firm, a securities fraud class-action lawsuit has been filed concerning the stock during a particular period. This alert emphasizes the significance of timely legal intervention for those impacted by stock depreciation.

What Happened?

Between March 26, 2025, and November 4, 2025, investors who purchased Soleno common stock may find themselves eligible for recovery options due to alleged material misstatements and omissions about the company's clinical trial program for diazoxide choline extended-release tablets, known as "DCCR." The summary of this situation reveals not only financial metrics but also serious allegations of misleading communications from Soleno's executives during this period.

Details of the Class Action

The lawsuit in question, City of Pontiac Police and Fire Retirement System v. Soleno Therapeutics, Inc., is being processed in the United States District Court for the Northern District of California. It specifically highlights accusations that the company downplayed critical safety concerns known to affect the clinical trials necessary for DCCR's launch. It identifies problems related to fluid retention among trial participants that could potentially compromise the drug's safety and efficacy.

Importantly, the allegations suggest that key information which would significantly influence investment decisions was not disclosed to shareholders, which ultimately undermines their financial stakes in Soleno.

The Aftermath of the Scorpion Report

A pivotal event during this time frame was the release of a report by Scorpion Capital, LLC on August 15, 2025. This publication brought to light numerous concerns regarding Soleno's Phase 3 clinical trial processes for DCCR, resulting in a 'disruption' in its launch momentum. Following this revelation, the number of patient start forms reportedly dropped, and patient discontinuations began to rise. The aftermath of these findings led to a dramatic decline in Soleno's stock price—more than 26%—which exacerbated the financial losses of investors.

What Should Affected Investors Do?

Investors who acquired Soleno common stock during the stated period and suffered monetary losses are urged to take prompt action. The deadline for filing to seek lead plaintiff status is May 5, 2026. This designation allows an investor to represent the interests of all class members in the lawsuit, aiming for a collective response to the alleged violations.

Kessler Topaz Meltzer & Check, LLP emphasizes that seeking legal counsel does not incur costs to the investor as they operate on a contingency fee basis. Investors can reach out to attorney Jonathan Naji at the firm for complimentary consultations to evaluate their eligibility for recovery.

About Kessler Topaz Meltzer & Check, LLP

Kessler Topaz Meltzer & Check, LLP has established a reputation as a leader in advocating for investors facing securities fraud and class action lawsuits. Based in Pennsylvania and California, the firm has successfully obtained over $25 billion for clients and is renowned for its advocacy in protecting the rights of both individuals and institutions affected by corporate malfeasance.

Conclusion

In conclusion, the allegations against Soleno Therapeutics are serious and pose substantial implications for the affected investors. If you are among those who invested in Soleno during the specified period, it is paramount to understand your legal rights and options to potentially recover losses incurred during this timeframe.

For further information, investors can explore the resources available through Kessler Topaz Meltzer & Check, LLP's official website.